Omalizumab beyond asthma

ABSTRACT: Introduction: Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient’s symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting...

Full description

Autores:
Sánchez Caraballo, Jorge Mario
Ramírez Giraldo, Ruth Helena
Diez Zuluaga, Libia Susana
Sus Carrizosa, Sara
Echenique, Alejandro
Olivares Gómez, María Margarita
Cardona Villa, Ricardo
Tipo de recurso:
Review article
Fecha de publicación:
2012
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/21273
Acceso en línea:
http://hdl.handle.net/10495/21273
Palabra clave:
Alergia e Inmunología
Allergy and Immunology
Anafilaxia
Anaphylaxis
Eccema
Eczema
Dermatitis Atópica
Dermatitis, Atopic
Eosinofilia
Eosinophilia
Omalizumab
Mastocitosis
Mastocytosis
Urticaria
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id UDEA2_5a5e2ad5ae7d4b6ee485bb9abeb20cbe
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/21273
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv Omalizumab beyond asthma
title Omalizumab beyond asthma
spellingShingle Omalizumab beyond asthma
Alergia e Inmunología
Allergy and Immunology
Anafilaxia
Anaphylaxis
Eccema
Eczema
Dermatitis Atópica
Dermatitis, Atopic
Eosinofilia
Eosinophilia
Omalizumab
Mastocitosis
Mastocytosis
Urticaria
title_short Omalizumab beyond asthma
title_full Omalizumab beyond asthma
title_fullStr Omalizumab beyond asthma
title_full_unstemmed Omalizumab beyond asthma
title_sort Omalizumab beyond asthma
dc.creator.fl_str_mv Sánchez Caraballo, Jorge Mario
Ramírez Giraldo, Ruth Helena
Diez Zuluaga, Libia Susana
Sus Carrizosa, Sara
Echenique, Alejandro
Olivares Gómez, María Margarita
Cardona Villa, Ricardo
dc.contributor.author.none.fl_str_mv Sánchez Caraballo, Jorge Mario
Ramírez Giraldo, Ruth Helena
Diez Zuluaga, Libia Susana
Sus Carrizosa, Sara
Echenique, Alejandro
Olivares Gómez, María Margarita
Cardona Villa, Ricardo
dc.subject.decs.none.fl_str_mv Alergia e Inmunología
Allergy and Immunology
Anafilaxia
Anaphylaxis
Eccema
Eczema
Dermatitis Atópica
Dermatitis, Atopic
Eosinofilia
Eosinophilia
Omalizumab
Mastocitosis
Mastocytosis
Urticaria
topic Alergia e Inmunología
Allergy and Immunology
Anafilaxia
Anaphylaxis
Eccema
Eczema
Dermatitis Atópica
Dermatitis, Atopic
Eosinofilia
Eosinophilia
Omalizumab
Mastocitosis
Mastocytosis
Urticaria
description ABSTRACT: Introduction: Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient’s symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting from this blockage. Because other diseases have an important IgE mediation in their physiopathology, the question arises as to if omalizumab would be useful in the treatment of other IgE-mediated diseases. Objective: We present an overview of the experimental studies and clinical reports evaluating the use of omalizumab in diseases different to asthma including atopic dermatitis, urticaria, eosinophilic gastrointestinal disorders, idiopathic anaphylaxis, latex allergy, hymenoptera venom allergy, and other IgE diseases. Methods: We reviewed the literature using PUBMED, EMBASE, and LILACS for publications which used omalizumab in the treatment of patients with allergic diseases or any other diseases. Complete articles published in English, Spanish or Portuguese were included. Conclusion: There is not enough evidence to support the regular use of omalizumab in IgE diseases other than asthma. However, some experimental and clinical investigations indicate that omalizumab could be a therapeutic option in several allergic diseases like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders. More control studies are needed in each IgE disease to evaluate the efficacy and safety of omalizumab in IgE mediated diseases.
publishDate 2012
dc.date.issued.none.fl_str_mv 2012
dc.date.accessioned.none.fl_str_mv 2021-07-29T15:16:03Z
dc.date.available.none.fl_str_mv 2021-07-29T15:16:03Z
dc.type.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.hasversion.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_dcae04bc
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ARTREV
dc.type.local.spa.fl_str_mv Artículo de revisión
format http://purl.org/coar/resource_type/c_dcae04bc
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Sánchez J, Ramírez R, Díez S, Sus S, Echenique A, Olivares M, Cardona R. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011.
dc.identifier.issn.none.fl_str_mv 0301-0546
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10495/21273
dc.identifier.doi.none.fl_str_mv 10.1016/j.aller.2011.09.011
dc.identifier.eissn.none.fl_str_mv 1578-1267
identifier_str_mv Sánchez J, Ramírez R, Díez S, Sus S, Echenique A, Olivares M, Cardona R. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011.
0301-0546
10.1016/j.aller.2011.09.011
1578-1267
url http://hdl.handle.net/10495/21273
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Allergol. immunopatol.
dc.rights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.accessrights.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.format.extent.spa.fl_str_mv 10
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Sociedad Española de Inmunología Clínica y Alergología Pediátrica
Elsevier
dc.publisher.group.spa.fl_str_mv Grupo de Alergología Clínica y Experimental (GACE)
dc.publisher.place.spa.fl_str_mv Murcia, España
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/1/SanchezJorge_2012_OmalizumabBeyondAsthma.pdf
https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/2/license_rdf
https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/3/license.txt
bitstream.checksum.fl_str_mv 29f06879526f8ec56484c374576d0924
b88b088d9957e670ce3b3fbe2eedbc13
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad de Antioquia
repository.mail.fl_str_mv andres.perez@udea.edu.co
_version_ 1812173133527908352
spelling Sánchez Caraballo, Jorge MarioRamírez Giraldo, Ruth HelenaDiez Zuluaga, Libia SusanaSus Carrizosa, SaraEchenique, AlejandroOlivares Gómez, María MargaritaCardona Villa, Ricardo2021-07-29T15:16:03Z2021-07-29T15:16:03Z2012Sánchez J, Ramírez R, Díez S, Sus S, Echenique A, Olivares M, Cardona R. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011.0301-0546http://hdl.handle.net/10495/2127310.1016/j.aller.2011.09.0111578-1267ABSTRACT: Introduction: Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient’s symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting from this blockage. Because other diseases have an important IgE mediation in their physiopathology, the question arises as to if omalizumab would be useful in the treatment of other IgE-mediated diseases. Objective: We present an overview of the experimental studies and clinical reports evaluating the use of omalizumab in diseases different to asthma including atopic dermatitis, urticaria, eosinophilic gastrointestinal disorders, idiopathic anaphylaxis, latex allergy, hymenoptera venom allergy, and other IgE diseases. Methods: We reviewed the literature using PUBMED, EMBASE, and LILACS for publications which used omalizumab in the treatment of patients with allergic diseases or any other diseases. Complete articles published in English, Spanish or Portuguese were included. Conclusion: There is not enough evidence to support the regular use of omalizumab in IgE diseases other than asthma. However, some experimental and clinical investigations indicate that omalizumab could be a therapeutic option in several allergic diseases like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders. More control studies are needed in each IgE disease to evaluate the efficacy and safety of omalizumab in IgE mediated diseases.COL005956710application/pdfengSociedad Española de Inmunología Clínica y Alergología PediátricaElsevierGrupo de Alergología Clínica y Experimental (GACE)Murcia, Españainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVArtículo de revisiónhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc-nd/4.0/Omalizumab beyond asthmaAlergia e InmunologíaAllergy and ImmunologyAnafilaxiaAnaphylaxisEccemaEczemaDermatitis AtópicaDermatitis, AtopicEosinofiliaEosinophiliaOmalizumabMastocitosisMastocytosisUrticariaAllergol. immunopatol.Allergologia et Immunopathologia306315405ORIGINALSanchezJorge_2012_OmalizumabBeyondAsthma.pdfSanchezJorge_2012_OmalizumabBeyondAsthma.pdfArtículo de revisiónapplication/pdf295700https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/1/SanchezJorge_2012_OmalizumabBeyondAsthma.pdf29f06879526f8ec56484c374576d0924MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/2/license_rdfb88b088d9957e670ce3b3fbe2eedbc13MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD5310495/21273oai:bibliotecadigital.udea.edu.co:10495/212732022-12-27 12:21:41.726Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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